Meeting
2014 ASCO Annual Meeting
Differential response of neoadjuvant chemotherapy with taxane-carboplatin versus taxane-epirubicin in patients with locally advanced triple-negative breast cancer.
Authors
Jiayu Wang
Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Jiayu Wang , Binghe Xu , Qing Li , Pin Zhang , Peng Yuan , Fei Ma , Ying Fan , Yang Luo , Ruigang Cai , Qiao LI
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Triple-Negative Breast Cancer
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 1105)
DOI
10.1200/jco.2014.32.15_suppl.1105
Abstract #
1105
Poster Bd #
198
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Phase II study of neoadjuvant chemotherapy with a metronomic regimen of paclitaxel + cyclophosphamide + capecitabine followed by 5-fluorouracil + epirubicin + cyclophosphamide in operable triple-negative breast cancer (JBCRG-13 study).
First Author: Kenji Higaki
Poster
2020 ASCO Virtual Scientific Program
Neoadjuvant docetaxel + carboplatin versus epirubicin+cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label, phase II trial.
First Author: Liulu Zhang
Poster
2017 ASCO Annual Meeting
Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173.
First Author: Peter Schmid
Poster
2017 ASCO Annual Meeting
A randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab, a PD-L1 antibody, to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC).
First Author: Sibylle Loibl